Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | USP1 | O94782 | 1/20 | 0.47 |
| ▸ | USP19 | O94966 | 1/20 | 0.47 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7701209 | 0.93 | NPC1 (0.51) | IKBKBKDM4EHSD17B10PTPN1NR4A2 | |
| SCHEMBL7695337 | 0.91 | IKBKB (0.55) | IKBKBKDM4EHSD17B10PTPN1NR4A2 | |
| SCHEMBL3128951 | 0.91 | IKBKB (0.54) | IKBKBKDM4EHSD17B10PPARGNCOA2 | |
| SCHEMBL7699801 | 0.87 | ALDH1A1 (0.51) | IKBKBKDM4EHSD17B10PPARGNCOA2 | |
| SCHEMBL3127884 | 0.87 | IKBKB (0.56) | IKBKBKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL3124862 | 0.86 | IKBKB (0.71) | IKBKBKDM4EHSD17B10PPARGNCOA2 | |
| SCHEMBL7693588 | 0.84 | KDM4E (0.65) | KDM4EHSD17B10NR4A2ALDH1A1HPGD | |
| SCHEMBL975670 | 0.83 | HDAC6 (0.54) | IKBKBKDM4EHSD17B10NR4A2PPARG | |
| SCHEMBL8823122 | 0.82 | ALDH1A1 (0.50) | IKBKBKDM4EHSD17B10NR4A2PPARG | |
| SCHEMBL8823073 | 0.82 | NR4A2 (0.51) | IKBKBKDM4EHSD17B10NR4A2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| CN-1230166-C | Gyrase inhibitors and uses thereof | VERTEX PHARMA (US) | 2005-12-07 | — | — | CN | disclosed |
| EP-1315707-A1 | LIPO- OR AMPHIPHILIC SCINTILLATORS AND THEIR USE IN ASSAYS | SENSE PROTEOMIC LIMITED (GB) | 2003-06-04 | — | — | EP | disclosed |
| CN-1400898-A | Gyrase inhibitors and uses thereof | VERTEX PHARMA (US) | 2003-03-05 | — | — | CN | disclosed |
| EP-1251848-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1251849-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002014290-A1 | LIPO- OR AMPHIPHILIC SCINTILLATORS AND THEIR USE IN ASSAYS | SENSE PROTEOMIC LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001052845-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPOATED (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052846-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | IKBKB 1775/4885KDM4E 1047/4885HSD17B10 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.